Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.
The treatment, Yupelri, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210598s000lbl.pdf, is once-daily inhalable solution to be used by patients of chronic obstructive pulmonary disease (COPD), a lung disease characterized by wheezing or chronic cough.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.